Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.4MCash on Hand
9.1mo Cash Runway
Follow SPRC by emailGet an email when SPRC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SPRC, unsubscribe in one click. Privacy
📣 What SPRC Says Is Next
in 2026 · “The global antibiotics market is projected to reach approximately $58 billion in 2026, according to a report published by Mordor Intelligence entitled “ Antibiotics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031) ”,driven by the escalating challenge of antimicrobial resistance.”
Company press release, Feb 2, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Leadership SciSparc appointed Prof. Jacob Nagel, former head of Israel's National Security Council and former acting National Security Advisor to Prime Minister Netanyahu, to its Scientific Advisory Board for AI and Cybersecurity. The move supports its planned entry into the Agentic AI sector. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Financing SciSparc filed a preliminary resale prospectus covering up to 76,807,229 ordinary shares for a selling shareholder, tied to a $3.0 million convertible promissory note issued November 3, 2026 for a $2.55 million purchase price. Up to $10 million in notes may be issued in total. Form F-3 · SEC filing
Nov 3, 2026 ·
Financing SciSparc entered a securities purchase agreement with an institutional investor for up to $10,000,000 of convertible promissory notes. The initial $3,000,000 note was issued for a purchase price of $2,550,000, with warrants covering 11,457,269 ordinary shares at $0.5237 per share. Form 6-K · SEC filing
Oct 26, 2026 ·
Financing Entered an inducement letter with holder L.I.A Pure Capital Ltd. to exercise existing warrants for 405,728 ordinary shares at a reduced exercise price of $1.0 per share, from an original $4.929. Expected gross proceeds of approximately $405,728, closing on or about October 27, 2026. Form 6-K · SEC filing
Oct 23, 2026 ·
Clinical trial Subsidiary NeuroThera Labs completed manufacturing of SCI-110 and obtained European QP batch release for clinical trial supplies. All three sites for the Phase IIb Tourette Syndrome trial finished site initiation, with drug shipments expected in the near term and patient enrollment next. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Subsidiary NeuroThera's CliniQuantum reported a GPU-accelerated quantum-simulation platform ran about 16.8 times faster than a 64-vCPU CPU-only setup, analyzing 3,531 gene-expression features from 11 patients. The release says the benchmark does not establish clinical validity. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Earnings Reported H1 2026 net loss of $6,051K versus $9,412K a year earlier. Cash was $4,436K at June 30, 2026, and total equity rose to $11,271K from a deficiency of $(81)K, after the CliniQuantum consolidation and new share and warrant issuances. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
SciSparc furnished a press release saying subsidiary NeuroThera and partner Clearmind had three U.S. patent applications published covering combinations of LSD, ketamine and ibogaine with PEA, for potential uses in depression, PTSD, pain and substance use disorders. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SPRC holds $4.4M in cash and short-term investments and burns about $1.5M/quarter from operations,
an estimated runway of 9.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:30 · Moderate
Cash runway 9 months +30
Shelf registration (F-3, Nov 2026) +10
Raised after last reported balance sheet (Jan 2026) -10
Share count 365,444 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SPRC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPRC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.